查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1858271

思觉失调症药物市场：2025-2032年全球预测（按类型、治疗类别、作用机制、剂型、最终用户、患者环境和患者群体划分）

Schizophrenia Therapeutics Market by Type, Therapeutic Class, Mechanism of Action, Formulation Type, End Users, Patient Settings, Patient Demographics - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，思觉失调症治疗市场将成长至 91.4 亿美元，复合年增长率为 5.63%。

关键市场统计数据
基准年 2024 58.9亿美元
预计年份：2025年 62.1亿美元
预测年份 2032 91.4亿美元
复合年增长率 (%) 5.63%

思觉失调症：重点关注临床挑战、不断发展的治疗模式以及以患者为中心的创新需求

思觉失调症是神经精神病学中最复杂、最重要的领域之一，其治疗方法的发展与临床知识的进步、患者期望的改变以及法规结构的完善同步进行。本导论旨在透过概述临床需求、治疗方法方法的多样性以及正在重塑诊断和治疗路径的技术和科学趋势的融合，帮助读者了解当前的治疗格局。

临床医师和研究人员持续面临症状表现、治疗反应和合併症的差异，凸显了采取全面照护方法的必要性。过去十年，治疗选择已从传统的口服抗精神病药物扩展到长效注射剂、神经调控技术和辅助性心理社会干预，每种方法的疗效、依从性和耐受性各不相同。同时，生物标记、影像学和数位化评估工具的进步提高了诊断准确性，并使治疗方案的调整更加及时。

重要的是，患者及其看护者越来越倾向于寻求能够兼顾症状控制和生活品质（QOL）的治疗方法，例如认知功能、社会融入和工作能力。因此，创新者和医疗服务提供者正致力于整合药物治疗、心理疗法和数位化支持，并促进医院、门诊和社区等不同医疗环境中的协作式医疗服务。本报告透过阐明这些潜在趋势，并重点关注临床需求、科学进步和商业性机会之间的交集，为更深入的分析奠定了基础。

识别将重塑思觉失调症治疗的变革性转变，包括精准精神病学、数位疗法、长效製剂和整合式医疗服务模式。

思觉失调症的治疗格局正在经历一系列变革，这些变革正在改变治疗方法的研发、实施和评估方式。精准精神病学正从概念走向实践，其方法是透过生物标记、临床表现和治疗反应模式对患者进行分层。因此，研发计画的设计越来越倾向于针对更细分的、具有生物学依据的亚群，临床研发策略也更加重视适应性研究设计和富含生物标记的队列，以加速概念验证。

同时，包括缓释性注射剂和植入式的长效药物正在重新定义药物依从性模式，并改变社区和医疗机构的照护流程。数位疗法和远端监测工具为症状追踪和早期復发检测创造了新的切入点，从而能够进行更积极主动的干预。此外，将药物治疗与结构化心理治疗、认知矫正和社会支持相结合的综合护理模式正日益受到重视，因为它们关注的是患者最关心的功能性结果。

监管机构正采取更灵活的医疗设备和组合产品核准途径来应对这些变化，而支付方也开始认识到减少住院次数并带来持续功能改善的干预措施的长期价值。总而言之，这些变化为多学科合作创造了机会，并要求相关人员重新思考临床试验设计、商业化路径和上市后证据的生成。

评估2025年美国关税对思觉失调症药物供应链、临床营运和国际合作动态的累积影响

2025年推出的政策和贸易措施对思觉失调症药物生态系统产生了累积影响，改变了成本结构、供应链韧性和跨国合作动态。关税调整影响了活性药物原料药、专用诊断设备和某些医疗设备组件的分销，迫使製造商和经销商重新评估筹资策略和库存管理，以减轻潜在的中断。为此，许多机构加快了近岸外包，并使其供应商网路多元化，以确保生产的连续性并维持临床试验的进度。

除了製造业之外，关税也透过影响国际合作的经济效益，对研发产生了连锁反应。申办方在考虑全球临床试验地点时，重新评估了其选址标准，将总营运成本和物流复​​杂性纳入考量。同时，不断增加的成本压力促使企业采取措施提高营运效率，包括精简临床供应链、优化批量规模以及利用灵活的契约製造关係。

从支付方和提供方的角度来看，投入成本的变化促使各方重新重视价值证明和基于结果的合同，以期在控制预算的同时维持医疗服务的可及性。此外，价格环境也凸显了监管协调和与政策制定者进行策略合作的重要性，以确保患者能够及时获得创新治疗方法。总而言之，这些趋势强化了商业策略和供应策略协调一致以维持治疗药物供应和保障医疗服务连续性的必要性。

详细的細項分析揭示了思觉失调症治疗中治疗方法类型、治疗领域、作用机制、剂型、最终用户、临床环境和人口统计学方面的细微差别

对细分市场的深入理解有助于阐明治疗方案的发展和服务提供如何与患者需求和临床情况相符。治疗方法依类型分为非药物疗法和药物疗法。非药物疗法包括认知行为疗法、电痉挛疗法和家庭疗法，而药物疗法则涵盖注射剂和口服药物，每种疗法在依从性、给药和监测方面都面临着不同的挑战。

依治疗类别划分，产品组合包括抗精神病药物、情绪稳定剂和选择性血清素再回收抑制剂。抗精神病药物进一步分为第一代和第二代药物，这一区分指南副作用管理、耐受性和长期安全性方面的决策。作用机转也是一项重要的分类标准，涵盖多巴胺受体拮抗剂、麸胺酸调节剂以及血清素和多巴胺活性调节剂，指南以改善难治性症状和认知障碍为目标的标靶研发策略。

製剂类型对于患者的用药便利性和药物动力学都至关重要，其范围涵盖从插片和贴片到液体和固态片剂，并影响患者的依从性和临床监测。最终使用者包括居家医疗、医院、精神科诊所和研究机构，这些机构共同决定了通路、培训需求和支援模式。患者就诊环境分为住院和门诊，影响治疗方案的选择和临床监测的强度。此外，患者群体又细分为成人、老年和儿童患者，每个亚组都有其独特的治疗重点、安全考量和监管途径。全面考虑患者群体细分有助于相关人员调整开发计划、商业策略和医疗服务模式，使其与不同的临床和营运实际情况相适应。

影响思觉失调症药物取得、研究和商业化的区域趋势和战略要务（美洲、欧洲、中东和非洲、亚太地区）

区域趋势对思觉失调症药物的研发、核准、报销和应用有显着影响。了解这些差异对于制定有效的全球策略至关重要。在美洲，临床研发基础设施完善、支付方环境相对成熟，以及数位医疗解决方案日益普及，都为新治疗方法的快速推广提供了支持。然而，都市区地区在医疗资源取得方面的差异以及社区服务的差异，需要製定个人化的分发和推广策略。

欧洲、中东和非洲地区各国的监管路径和医疗保健资金筹措模式差异显着，导致准入条件和实施时间各不相同。许多地区高度重视卫生技术评估 (HTA) 和疗效比较证据，尤其註重可靠的真实世界数据和长期疗效研究。此外，某些市场的医疗资源限制凸显了培训计画和与当地医疗机构合作的重要性，以确保复杂治疗方法的合理应用。

在亚太地区，临床研究的快速投入、强大的生产能力以及日益普及的数位医疗，为创新和规模化发展创造了有利环境。然而，打入市场策略必须考虑不同的监管要求、报销环境以及与心理健康相关的文化因素。区域洞察表明，针对监管、证据生成和商业部署采取差异化策略，并充分考虑当地的临床实践和医疗体系优先事项，将有助于实现最永续的患者可及性和商业性效益。

思觉失调症治疗领域主要企业的策略与竞争趋势：聚焦伙伴关係、产品线多元化、数位整合与病人参与策略

在思觉失调症治疗领域，各公司之间的竞争日益激烈，主要体现在对治疗方法创新、策略联盟和综合护理解决方案的关注。成熟的生物製药公司持续投资于分子优化、製剂改进和现有疗法的生命週期管理，而新兴的生物技术公司则专注于新型作用机制和生物标记主导的候选药物，以应对难治性患者群体。

同时，科技公司和数位健康领域的新兴参与企业正在开髮用于症状监测、药物依从性支持和认知改善的辅助平台，这不仅拓宽了竞争格局，也为跨行业合作创造了机会。合约研究组织 (CRO) 和专业生产合作伙伴在提供製剂放大生产和监管申报方面的专业知识方面发挥关键作用，从而缩短了新治疗方法进入临床试验的时间。经营模式正朝着许可、合作开发和策略性收购相结合的方向转变，使企业能够整合互补能力并降低研发风险。

从商业性角度来看，企业优先考虑能够证明产品具有显着功能性益处的证据，透过基于绩效的合约与支付方建立联繫，并建立完善的患者支援计划，以提高治疗依从性和患者满意度。那些能够将研发重点与实际临床需求结合，并投资于可扩展的商业化平台和医护人员培训的经营团队，将更有能力在创造价值的同时改善病患疗效。

为行业领导者提供切实可行的建议，以加速思觉失调症治疗领域的创新，确保供应弹性，向支付方证明价值，并改善患者预后

产业领导者应采取一系列协同行动，将科学进步转化为持续的临床和商业性效益。首先，各机构应优先投资于长效製剂和联合治疗，以提高患者依从性并降低復发率，同时制定严谨的证据方案，重点关注临床医生和支付方重视的功能性结果。其次，领导者应将数位化工具融入研发流程和诊疗路径，以支援远端监测、早期復发检测和个人化依从性干预，从而增强不同医疗机构间诊疗的连续性。

第三，必须将供应链韧性作为策略重点。这包括供应商多元化、区域製造伙伴关係以及製定紧急时应对计画，以减轻供应中断及其对患者照护的影响。第四，商业机构应儘早与支付方接洽，协商利用真实世界数据和卫生经济学模型评估长期价值和减少急诊护理利用的报销框架。第五，与学术机构、患者权益倡导团体和行为健康服务提供者建立合作关係，将有助于创新技术快速应用于日常实践，并确保干预措施能够响应实际经验。

最后，各机构应采取适应性强的监管和临床开发策略，包括利用生物标记、适应性设计和可操作的终点指标来有效证明疗效。透过协调研发、商业和营运等各职能部门的工作，企业领导者得以在复杂的治疗环境中，既改善病患预后，又实现竞争优势。

本分析采用了一套严谨的调查方法，详细说明了主要研究和次要研究、相关利益者访谈、临床证据综合以及资料检验方法。

本执行摘要的分析采用了混合方法研究，将质性研究结果与系统性证据综合相结合，以确保研究结果的稳健性和相关性。主要研究包括对临床医生、支付方代表、临床营运总监和患者权益倡导团体进行结构化访谈，以确定第一线挑战、实施障碍和证据产生的优先事项。这些访谈有助于确定关键问题，并突显哪些领域最需要收集更多资料。

我们的二次研究整合了同行评审文献、监管指导文件、临床试验註册资讯和产品标籤，以绘製治疗机制、安全讯号和核准途径。此外，我们也分析了试验活动和研发管线讯息，以识别治疗方法趋势和研发瓶颈。跨资讯来源的资料三角验证支持了我们研究结果的交叉检验，并有助于调和相关利益者观点与已发表证据之间的差异。

透过预先设定的纳入标准、对证据来源的定性评估以及与临床专家进行反覆审查以检验，确保了分析的严谨性。研究明确承认了数据可用性的区域差异和不断变化的法规环境等局限性，并在适当情况下应用了敏感性分析来检验假设。总体而言，该调查方法建构了一个思觉失调症，可为策略决策提供支援。

综合洞察整合了临床、商业性和监管趋势，以指南策略决策，并优先考虑以患者为中心的思觉失调症治疗开发。

总之，思觉失调症药物治疗领域呈现出科学创新、治疗模式变革和复杂商业性动态的特点，这些因素共同为相关人员创造了机会，同时也带来了责任。药理学、数位医疗和社会心理介入的进步为改善症状管理和功能恢復提供了切实的前景，但要取得持续进展，需要协调一致的循证医学证据、适应性强的监管合作以及以患者为中心的服务提供。

此外，供应链中断和政策变化等外部压力凸显了策略韧性和营运灵活性的重要性。整合多元治疗方法、展现实际价值并促进整个医疗生态系统伙伴关係的机构，将更有能力应对不确定性，同时扩大有效治疗的覆盖范围。最终，专注于对患者至关重要的结果——认知功能、社会融入和长期稳定性——将成为成功创新和公平实施的基石，并将指导未来在该领域的投资和合作。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 思觉失调症治疗流程中个人化药物基因体学方法的出现
  • 快速采用数位治疗方法和人工智慧驱动的监测平台来预防復发
  • 人们对长效注射剂的兴趣日益浓厚，以提高患者依从性。
  • 为难治性思觉失调症患者族群开发新型麸胺酸受体调变器
  • 增加针对思觉失调症神经发炎的抗发炎药物的投资
  • 整合真实世界证据研究以支持标籤和报销决策

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章思觉失调症治疗药物市场（按类型划分）

  • 非药物疗法
    • 认知行为治疗（CBT）
    • 电痉挛疗法（ECT）
    • 家庭治疗
  • 药物治疗
    • 注射药物
    • 口服药物

第九章思觉失调症治疗药物市场（依治疗类别划分）

  • 抗精神病药物
    • 第一代抗精神病药物
    • 第二代抗精神病药物
  • 情绪稳定剂
  • 选择性血清素再回收抑制剂

第十章思觉失调症治疗药物市场依作用机制划分

  • 多巴胺受体拮抗剂
  • 麸胺酸调变器
  • 血清素和多巴胺活性调节剂

第十一章思觉失调症剂型划分）

  • 插片和补丁
  • 液体
  • 固态片剂

第十二章思觉失调症治疗药物市场（依最终用户划分）

  • 居家医疗环境
  • 医院
  • 精神病诊所
  • 研究所

第十三章思觉失调症治疗药物市场（依病患环境划分）

  • 住院治疗
  • 门诊治疗

第十四章 按患者群体分類的思觉失调症治疗药物市场

  • 成年患者
  • 老年患者
  • 儿科患者

第十五章 各地区思觉失调症治疗药物市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十六章思觉失调症治疗药物市场（按组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十七章 各国思觉失调症治疗药物市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十八章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • AbbVie Inc.
    • Acadia Pharmaceuticals Inc.
    • Alkermes Plc
    • Amneal Pharmaceuticals, LLC
    • Astellas Pharma Inc.
    • AstraZeneca plc
    • BioXcel Therapeutics, Inc.
    • Boehringer Ingelheim International GmbH
    • Bristol Myers Squibb Company
    • Cipla Limited
    • Delpor, Inc.
    • Dr. Reddy's Laboratories Ltd.
    • Eli Lilly and Company
    • Gedeon Richter Plc
    • GlaxoSmithKline plc.
    • Glenmark Pharmaceuticals Limited
    • Johnson & Johnson Services, Inc.
    • Lundbeck A/S
    • Lupin Limited
    • Luye Pharma Group Ltd
    • Lyndra Therapeutics Inc
    • Meiji Holdings Co., Ltd.
    • Merck & Co., Inc.
    • Neurocrine Biosciences, Inc.
    • Novartis AG
    • Otsuka Holdings Co., Ltd.
    • Pfizer Inc.
    • Reviva Pharmaceuticals Holdings, Inc.
    • Sanofi SA
    • Sumitomo Pharma Co., Ltd.
    • Sun Pharmaceutical Industries Limited
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries Ltd.
    • Torrent Pharmaceuticals Ltd.
    • Vanda Pharmaceuticals Inc.
Product Code: MRR-8E22B61932B8

The Schizophrenia Therapeutics Market is projected to grow by USD 9.14 billion at a CAGR of 5.63% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 5.89 billion
Estimated Year [2025] USD 6.21 billion
Forecast Year [2032] USD 9.14 billion
CAGR (%) 5.63%

A concise overview of schizophrenia therapeutics highlighting clinical challenges, evolving treatment paradigms, and the imperative for patient-centered innovation

Schizophrenia remains one of the most complex and consequential areas within neuropsychiatry, and therapeutics development has advanced alongside evolving clinical understanding, patient expectations, and regulatory frameworks. This introduction orients readers to the current therapeutic landscape by summarizing the clinical imperatives, the diversity of treatment modalities, and the converging technological and scientific trends that are reshaping diagnostic and therapeutic pathways.

Clinicians and researchers continue to confront heterogeneity in symptom presentation, treatment response, and comorbidity, which together underscore the need for a multifaceted approach to care. Over the past decade, treatment options have expanded beyond traditional oral antipsychotics to include long-acting injectables, neuromodulation techniques, and adjunctive psychosocial interventions, each offering distinct efficacy, adherence, and tolerability profiles. Simultaneously, advancements in biomarkers, imaging, and digital assessment tools are improving diagnostic precision and enabling more timely therapeutic adjustments.

Importantly, patients and caregivers increasingly demand treatments that balance symptom control with quality-of-life considerations such as cognitive function, social integration, and employment capacity. As a result, innovators and providers are aligning around strategies that integrate pharmacology, psychotherapy, and digital supports, and that foster coordinated care across hospital, outpatient, and community settings. This report sets the stage for deeper analysis by clarifying these foundational dynamics and highlighting where clinical need, scientific progress, and commercial opportunity intersect.

Identifying transformative shifts reshaping schizophrenia care including precision psychiatry, digital therapeutics, long-acting modalities, and integrated care delivery models

The landscape of schizophrenia therapeutics is undergoing a series of transformative shifts that alter how treatments are developed, delivered, and evaluated. Precision psychiatry is moving from concept to practice through efforts to stratify patients by biomarkers, phenomenology, and treatment response patterns. As a consequence, development programs are increasingly designed to target narrower, biologically informed subpopulations, and clinical development strategies emphasize adaptive trial designs and biomarker-enriched cohorts to accelerate proof of concept.

At the same time, long-acting modalities, including extended-release injectables and implantable formulations, are redefining adherence paradigms and altering care workflows in both community and institutional settings. Digital therapeutics and remote monitoring tools are creating new touchpoints for symptom tracking and early relapse detection, thereby enabling more proactive interventions. Moreover, integrated care models that combine pharmacological treatment with structured psychotherapies, cognitive remediation, and social supports are gaining traction because they address functional outcomes that patients value most.

Regulatory agencies are responding with more flexible pathways for devices and combination products, and payers are beginning to recognize the long-term value of interventions that reduce hospitalization and improve sustained functioning. Taken together, these shifts create opportunities for interdisciplinary collaboration and require stakeholders to rethink clinical trial design, commercialization pathways, and post-market evidence generation.

Assessing the cumulative impact of United States tariffs in 2025 on schizophrenia therapeutic supply chains, clinical operations, and international collaboration dynamics

Policy and trade measures introduced in 2025 have exerted a cumulative influence on the schizophrenia therapeutics ecosystem by altering cost structures, supply chain resilience, and cross-border collaboration dynamics. Tariff adjustments affected the flow of active pharmaceutical ingredients, specialized diagnostic equipment, and certain device components, prompting manufacturers and distributors to reassess sourcing strategies and inventory management to mitigate potential disruptions. In response, many organizations accelerated nearshoring and diversified supplier networks to preserve manufacturing continuity and maintain clinical trial timelines.

Beyond manufacturing, tariffs have implications for research and development partnerships by influencing the economics of international collaboration. Sponsors weighing global trial sites reassessed site selection criteria to account for total cost of operations and logistics complexity. Simultaneously, heightened cost pressures stimulated operational efficiency efforts, including streamlining clinical supply chains, optimizing batch sizes, and leveraging contract manufacturing relationships with greater flexibility.

From the payer and provider perspective, changes in input costs encouraged renewed emphasis on value demonstration and outcomes-based contracting, as institutions seek to preserve access while managing budgets. Moreover, the tariff environment highlighted the importance of regulatory harmonization and strategic engagement with policy makers to ensure that patients continue to receive timely access to innovative therapies. Overall, these dynamics reinforced the need for coordinated commercial and supply strategies to sustain therapeutic availability and protect continuity of care.

Deep-dive segmentation insights that unpack therapy types, therapeutic classes, mechanisms, formulations, end users, care settings, and demographic nuances for schizophrenia care

A nuanced understanding of segmentation illuminates how therapeutic development and service delivery align with patient needs and clinical contexts. Based on type, treatments split into non-pharmacological therapies and pharmacological therapies, where non-pharmacological approaches include therapies such as cognitive-behavioral therapy, electroconvulsive therapy, and family therapy, and pharmacological approaches encompass both injectable medications and oral medications, each carrying distinct implications for adherence, administration, and monitoring.

When viewed by therapeutic class, the portfolio includes antipsychotics, mood stabilizers, and selective serotonin reuptake inhibitors, with antipsychotics further categorized into first-generation and second-generation agents; these distinctions inform decisions around side-effect management, tolerability profiles, and long-term safety considerations. Mechanism of action also provides a critical lens for segmentation, covering dopamine receptor antagonists, glutamate modulators, and serotonin dopamine activity modulators, and guiding targeted development strategies that aim to address refractory symptoms or cognitive deficits.

Formulation type matters for both patient convenience and pharmacokinetics, ranging from inserts and patches to liquid solutions and solid tablets, and influencing adherence patterns and clinical monitoring. End users span homecare settings, hospitals, mental health clinics, and research institutes, which collectively determine distribution channels, training needs, and support models. Patient settings dichotomize into inpatient care and outpatient care, shaping therapeutic selection and intensity of clinical oversight. Finally, patient demographics differentiate adult, geriatric, and pediatric patients, each subgroup presenting unique therapeutic priorities, safety considerations, and regulatory pathways. Considering segmentation holistically enables stakeholders to tailor development plans, commercial strategies, and care delivery models to distinct clinical and operational realities.

Regional dynamics and strategic imperatives across the Americas, Europe Middle East and Africa, and Asia-Pacific that influence access, research, and commercialization of schizophrenia therapies

Regional dynamics significantly influence how schizophrenia therapies are developed, approved, reimbursed, and adopted, and understanding these distinctions is essential for effective global strategies. In the Americas, clinical development infrastructure, a relatively mature payer landscape, and growing acceptance of digital health solutions support rapid uptake of new therapeutic modalities; however, access disparities across urban and rural settings and variability in community-based services require tailored distribution and engagement strategies.

In Europe, Middle East and Africa, regulatory pathways and healthcare funding models vary considerably across countries, producing a mosaic of access conditions and adoption timelines. Many jurisdictions emphasize health technology assessments and comparative effectiveness evidence, which places a premium on robust real-world data and long-term outcomes research. Additionally, capacity constraints in certain markets underscore the importance of training programs and partnerships with local providers to ensure appropriate deployment of complex therapies.

Across Asia-Pacific, rapid investment in clinical research, strong manufacturing capabilities, and increasing digital health uptake create fertile conditions for both innovation and scale, but market entry strategies must account for diverse regulatory expectations, reimbursement environments, and cultural considerations related to mental health. Taken together, regional insight suggests that a differentiated approach to regulatory engagement, evidence generation, and commercial rollout, sensitive to local clinical practices and health system priorities, will produce the most sustainable patient access and commercial outcomes.

Key company strategies and competitive dynamics in schizophrenia therapeutics emphasizing partnerships, pipeline diversification, digital integration, and patient engagement strategies

Competitive dynamics among companies operating in the schizophrenia therapeutics space are driven by innovation in modality, strategic partnerships, and a growing emphasis on integrated care solutions. Established biopharmaceutical firms continue to invest in molecule optimization, formulation improvements, and lifecycle management for legacy therapies, while emerging biotechnology companies focus on novel mechanisms of action and biomarker-driven candidates that address treatment-resistant populations.

Concurrently, technology companies and digital health entrants are developing adjunctive platforms for symptom monitoring, adherence support, and cognitive remediation, which expands the competitive set and creates opportunities for cross-sector collaborations. Contract research organizations and specialized manufacturing partners play a critical role in accelerating time to clinic for novel modalities, offering expertise in formulation scale-up and regulatory filings. Business models increasingly reflect a blend of licensing, co-development, and strategic acquisitions, enabling firms to combine complementary capabilities and de-risk development pathways.

From a commercial standpoint, companies prioritize evidence generation that demonstrates meaningful functional benefits, engages payers through outcomes-based agreements, and builds robust patient support programs to improve persistence and satisfaction. Leadership teams that align R&D priorities with real-world clinical needs, and that invest in scalable commercialization engines and provider education, will be well positioned to capture value while advancing patient outcomes.

Actionable recommendations for industry leaders to accelerate innovation, ensure supply resilience, demonstrate value to payers, and enhance patient outcomes in schizophrenia care

Industry leaders must pursue a set of coordinated actions to convert scientific advances into durable clinical and commercial gains. First, organizations should prioritize investments in long-acting formulations and combination approaches that improve adherence and reduce relapse, while concurrently developing rigorous evidence packages that highlight functional outcomes valued by clinicians and payers. Second, leaders should embed digital tools into development and care pathways to support remote monitoring, early relapse detection, and personalized adherence interventions, thereby enhancing continuity of care across settings.

Third, supply chain resilience must be elevated to a strategic priority through supplier diversification, regional manufacturing partnerships, and contingency planning to mitigate the kinds of disruptions that affect availability and patient care. Fourth, commercial teams should engage payers early, leveraging real-world evidence and health economic modeling to negotiate reimbursement frameworks that reward long-term value and reduced acute care utilization. Fifth, cultivating collaborative relationships with academic centers, patient advocacy groups, and behavioral health providers will accelerate the translation of innovations into routine practice and ensure that interventions respond to lived experience.

Finally, organizations should adopt adaptive regulatory and clinical development strategies that use biomarkers, adaptive designs, and pragmatic endpoints to demonstrate benefit efficiently. By aligning these actions across R&D, commercial, and operational functions, leaders can both enhance patient outcomes and sustain competitive differentiation in a complex therapeutic landscape.

Robust research methodology detailing primary and secondary approaches, stakeholder interviews, clinical evidence synthesis, and data validation techniques used in this analysis

The analysis underpinning this executive summary relied on a mixed-methods research approach that blended qualitative insights with systematic evidence synthesis to ensure robustness and relevancy. Primary research included structured interviews with clinicians, payer representatives, clinical operations leaders, and patient advocates to surface frontline challenges, adoption barriers, and priorities for evidence generation. These conversations informed the framing of key questions and highlighted where supplementary data collection would be most valuable.

Secondary research synthesized peer-reviewed literature, regulatory guidance documents, clinical trial registries, and product labeling to map therapeutic mechanisms, safety signals, and approval pathways. Additionally, trial activity and pipeline intelligence were examined to identify modality trends and development bottlenecks. Data triangulation across these sources supported cross-validation of findings and helped reconcile discrepancies between stakeholder perspectives and published evidence.

Analytical rigor was ensured through predefined inclusion criteria, quality appraisal of evidence sources, and iterative review cycles with clinical experts to validate interpretations. Limitations were acknowledged explicitly, including variability in regional data availability and evolving regulatory contexts, and sensitivity analyses were applied where appropriate to test assumptions. Overall, this methodology produced a balanced, actionable view of the schizophrenia therapeutics landscape that supports strategic decision making.

Concluding insights synthesizing clinical, commercial, and regulatory trends to guide strategic decision making and prioritize patient-centric therapeutic development in schizophrenia

In conclusion, the schizophrenia therapeutics landscape is characterized by scientific innovation, shifting care models, and complex commercial dynamics that together create both opportunities and responsibilities for stakeholders. Advances in pharmacology, digital health, and psychosocial interventions offer tangible prospects for improving symptom control and functional recovery, yet sustained progress depends on coordinated evidence generation, adaptive regulatory engagement, and patient-centered service delivery.

Moreover, external pressures such as supply chain disruptions and policy changes underscore the need for strategic resilience and operational agility. Organizations that integrate diverse modalities, demonstrate real-world value, and cultivate partnerships across the healthcare ecosystem will better navigate uncertainty while expanding access to effective care. Ultimately, a focus on outcomes that matter to patients-cognitive function, social integration, and long-term stability-will serve as the touchstone for successful innovation and equitable implementation, guiding future investments and collaborative efforts across the field.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emergence of personalized pharmacogenomic approaches in schizophrenia treatment pipelines
  • 5.2. Rapid adoption of digital therapeutics and AI-enabled monitoring platforms for relapse prevention
  • 5.3. Growing emphasis on long-acting injectable formulations to improve patient adherence rates
  • 5.4. Expansion of novel glutamate receptor modulators for treatment-resistant schizophrenia populations
  • 5.5. Increasing investment in anti-inflammatory agents targeting neuroinflammation in schizophrenia
  • 5.6. Integration of real-world evidence studies to support label expansions and reimbursement decisions

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Schizophrenia Therapeutics Market, by Type

  • 8.1. Non-Pharmacological Therapies
    • 8.1.1. Cognitive-Behavioral Therapy (CBT)
    • 8.1.2. Electroconvulsive Therapy (ECT)
    • 8.1.3. Family Therapy
  • 8.2. Pharmacological Therapies
    • 8.2.1. Injectable Medications
    • 8.2.2. Oral Medications

9. Schizophrenia Therapeutics Market, by Therapeutic Class

  • 9.1. Antipsychotics
    • 9.1.1. First-Generation Antipsychotics
    • 9.1.2. Second-Generation Antipsychotics
  • 9.2. Mood Stabilizers
  • 9.3. Selective Serotonin Reuptake Inhibitors

10. Schizophrenia Therapeutics Market, by Mechanism of Action

  • 10.1. Dopamine Receptor Antagonists
  • 10.2. Glutamate Modulators
  • 10.3. Serotonin Dopamine Activity Modulators

11. Schizophrenia Therapeutics Market, by Formulation Type

  • 11.1. Inserts and Patches
  • 11.2. Liquid Solutions
  • 11.3. Solid Tablets

12. Schizophrenia Therapeutics Market, by End Users

  • 12.1. Homecare Settings
  • 12.2. Hospitals
  • 12.3. Mental Health Clinics
  • 12.4. Research Institutes

13. Schizophrenia Therapeutics Market, by Patient Settings

  • 13.1. Inpatient Care
  • 13.2. Outpatient Care

14. Schizophrenia Therapeutics Market, by Patient Demographics

  • 14.1. Adult Patients
  • 14.2. Geriatric Patients
  • 14.3. Pediatric Patients

15. Schizophrenia Therapeutics Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Schizophrenia Therapeutics Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Schizophrenia Therapeutics Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. Competitive Landscape

  • 18.1. Market Share Analysis, 2024
  • 18.2. FPNV Positioning Matrix, 2024
  • 18.3. Competitive Analysis
    • 18.3.1. AbbVie Inc.
    • 18.3.2. Acadia Pharmaceuticals Inc.
    • 18.3.3. Alkermes Plc
    • 18.3.4. Amneal Pharmaceuticals, LLC
    • 18.3.5. Astellas Pharma Inc.
    • 18.3.6. AstraZeneca plc
    • 18.3.7. BioXcel Therapeutics, Inc.
    • 18.3.8. Boehringer Ingelheim International GmbH
    • 18.3.9. Bristol Myers Squibb Company
    • 18.3.10. Cipla Limited
    • 18.3.11. Delpor, Inc.
    • 18.3.12. Dr. Reddy's Laboratories Ltd.
    • 18.3.13. Eli Lilly and Company
    • 18.3.14. Gedeon Richter Plc
    • 18.3.15. GlaxoSmithKline plc.
    • 18.3.16. Glenmark Pharmaceuticals Limited
    • 18.3.17. Johnson & Johnson Services, Inc.
    • 18.3.18. Lundbeck A/S
    • 18.3.19. Lupin Limited
    • 18.3.20. Luye Pharma Group Ltd
    • 18.3.21. Lyndra Therapeutics Inc
    • 18.3.22. Meiji Holdings Co., Ltd.
    • 18.3.23. Merck & Co., Inc.
    • 18.3.24. Neurocrine Biosciences, Inc.
    • 18.3.25. Novartis AG
    • 18.3.26. Otsuka Holdings Co., Ltd.
    • 18.3.27. Pfizer Inc.
    • 18.3.28. Reviva Pharmaceuticals Holdings, Inc.
    • 18.3.29. Sanofi S.A
    • 18.3.30. Sumitomo Pharma Co., Ltd.
    • 18.3.31. Sun Pharmaceutical Industries Limited
    • 18.3.32. Takeda Pharmaceutical Company Limited
    • 18.3.33. Teva Pharmaceutical Industries Ltd.
    • 18.3.34. Torrent Pharmaceuticals Ltd.
    • 18.3.35. Vanda Pharmaceuticals Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. EUROPE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. MIDDLE EAST SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. ASEAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GCC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. EUROPEAN UNION SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BRICS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. G7 SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. NATO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. SCHIZOPHRENIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 34. SCHIZOPHRENIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. SCHIZOPHRENIA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COGNITIVE-BEHAVIORAL THERAPY (CBT), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COGNITIVE-BEHAVIORAL THERAPY (CBT), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COGNITIVE-BEHAVIORAL THERAPY (CBT), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COGNITIVE-BEHAVIORAL THERAPY (CBT), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COGNITIVE-BEHAVIORAL THERAPY (CBT), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COGNITIVE-BEHAVIORAL THERAPY (CBT), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ELECTROCONVULSIVE THERAPY (ECT), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ELECTROCONVULSIVE THERAPY (ECT), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ELECTROCONVULSIVE THERAPY (ECT), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ELECTROCONVULSIVE THERAPY (ECT), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ELECTROCONVULSIVE THERAPY (ECT), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ELECTROCONVULSIVE THERAPY (ECT), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FAMILY THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FAMILY THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FAMILY THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FAMILY THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FAMILY THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FAMILY THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INJECTABLE MEDICATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INJECTABLE MEDICATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INJECTABLE MEDICATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INJECTABLE MEDICATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INJECTABLE MEDICATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INJECTABLE MEDICATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ORAL MEDICATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ORAL MEDICATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ORAL MEDICATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ORAL MEDICATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ORAL MEDICATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ORAL MEDICATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FIRST-GENERATION ANTIPSYCHOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FIRST-GENERATION ANTIPSYCHOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FIRST-GENERATION ANTIPSYCHOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FIRST-GENERATION ANTIPSYCHOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FIRST-GENERATION ANTIPSYCHOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FIRST-GENERATION ANTIPSYCHOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SECOND-GENERATION ANTIPSYCHOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SECOND-GENERATION ANTIPSYCHOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SECOND-GENERATION ANTIPSYCHOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SECOND-GENERATION ANTIPSYCHOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SECOND-GENERATION ANTIPSYCHOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SECOND-GENERATION ANTIPSYCHOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY GLUTAMATE MODULATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY GLUTAMATE MODULATORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY GLUTAMATE MODULATORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY GLUTAMATE MODULATORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY GLUTAMATE MODULATORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY GLUTAMATE MODULATORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SEROTONIN DOPAMINE ACTIVITY MODULATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SEROTONIN DOPAMINE ACTIVITY MODULATORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SEROTONIN DOPAMINE ACTIVITY MODULATORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SEROTONIN DOPAMINE ACTIVITY MODULATORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SEROTONIN DOPAMINE ACTIVITY MODULATORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SEROTONIN DOPAMINE ACTIVITY MODULATORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INSERTS AND PATCHES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INSERTS AND PATCHES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INSERTS AND PATCHES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INSERTS AND PATCHES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INSERTS AND PATCHES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INSERTS AND PATCHES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY LIQUID SOLUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY LIQUID SOLUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY LIQUID SOLUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY LIQUID SOLUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY LIQUID SOLUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY LIQUID SOLUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SOLID TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SOLID TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SOLID TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SOLID TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SOLID TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SOLID TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INPATIENT CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INPATIENT CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INPATIENT CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INPATIENT CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INPATIENT CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INPATIENT CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY OUTPATIENT CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY OUTPATIENT CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY OUTPATIENT CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY OUTPATIENT CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY OUTPATIENT CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY OUTPATIENT CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADULT PATIENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADULT PATIENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADULT PATIENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADULT PATIENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY GERIATRIC PATIENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY GERIATRIC PATIENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY GERIATRIC PATIENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY GERIATRIC PATIENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY GERIATRIC PATIENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY GERIATRIC PATIENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC PATIENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC PATIENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC PATIENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC PATIENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)

TAB